MedTrace Logo

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4

NCT06548815 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-08-12

No results posted yet for this study

Summary

This trial is conducted in China. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single-dose GZR4.

Conditions

Interventions

DRUG

GZR4

Ascending single doses - 4 dose levels.

DRUG

Placebo

Ascending single doses - 4 dose levels.

Sponsors & Collaborators

  • Gan and Lee Pharmaceuticals, USA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2023-03-24
Completion
2023-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06548815 on ClinicalTrials.gov